Kazia Therapeutics公布核内Pd-L1降解剂Ndl2引人注目的临床前及转化研究数据

美股速递
Jan 30

Kazia Therapeutics Limited (简称Kazia) 近日发布了其核内Pd-L1降解剂候选药物Ndl2的最新研究进展。数据显示,该药物在临床前及转化研究阶段展现出令人鼓舞的潜力。

研究结果突显了Ndl2在靶向核内Pd-L1蛋白降解方面的独特机制。这些发现为后续开发提供了坚实的科学依据,并预示着该疗法在相关疾病领域可能具有重要的应用价值。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10